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Antibiotics are the drugs that are used for treatment of infections caused by bacteria.1  
Administration of antibiotics is currently the most commonly used method for combating 
infections in modern medicine.  The use of antibiotics has not only saved patients’ lives, but they 
have also played a major role in other advances in medicine and surgery.2  This widespread use of 
antibiotics has led to a new problem termed as “antibiotic resistance.”3  Antibiotic resistance 
develops primarily due to overuse and misuse of antibiotics, which leads to proliferation of bacteria 
that do not respond to treatment with antibiotics.4  In other words, these bacteria are “resistant” to 
antibiotics.  
                                                        
1 See Combating Antibiotic Resistance, Food and Drug Administration, 
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm092810.htm (“FDA article on Combating 
Antibiotic Resistance”) (last visited Nov. 30, 2016); see also Lecia Bushak, A Brief History of Antibiotic 
Resistance: How a Medical Miracle Turned into the Biggest Public Health Danger of Our Time, Medical 
Daily (Feb. 17, 2016), http://www.medicaldaily.com/antibiotic-resistance-history-373773 (“Bushak 2016”) 
(“The term “antibiotic” has an extremely broad definition, describing the activity of any compound or 
chemical that can be applied to kill or inhibit bacteria that cause infectious diseases.”) (last visited Nov. 30, 
2016). 
2 See Lee Ventola, The Antibiotic Resistance Crisis, Part 1: Causes and Threats, 40 PHARMACY & 
THERAPEUTICS, 277, 278 (2015) (“Ventola 2015”) (“They have successfully prevented or treated 
infections that can occur in patients who are receiving chemotherapy treatments; who have chronic diseases 
such as diabetes, end-stage renal disease, or rheumatoid arthritis; or who have had complex surgeries such 
as organ transplants, joint replacements, or cardiac surgery.”).  
3 Id. at p. 277.  
4 See FDA article on Combating Antibiotic Resistance, supra note 1. 






Antibiotic resistance is a growing public health concern not only in United States, but 
worldwide.5  According to the Centers for Disease Control and Prevention (“CDC”), in excess of 
2 million patients suffer from antibiotic resistant infections, which leads to about 23,000 deaths.6  
The ineffectiveness of antibiotics to treat infections leads to use of more and a higher dose of 
antibiotics and longer and more complicated illnesses.  The patients suffering from antibiotic 
resistant infections may transfer the infections to other people.  Moreover, the rate of occurrences 
of antibiotic resistance bacterial infections, in general, are increasing.7  For at least these reasons, 
antibiotic resistance has become a worldwide public health problem, which should be addressed.  
Although the government, through FDA and CDC have taken some steps to address the 
problem of antibiotic resistance, it is clear that more urgent attention and action is required to 
combat this problem.  This paper will first discuss the primary causes for development antibiotic 
resistance, and will subsequently discuss some relevant approaches to alleviate this problem.  In 
short, this paper will focus on strategies to curb the human activities leading to proliferation of 
antibiotic resistance, and some potential solutions to discover new antibiotics that are effective 
against the resistant strains of bacteria.  None of the approaches discussed herein will be 
exclusively capable of eliminating antibiotic resistance, but through a combination of several 
interventions, we might be able to develop effective strategies to combat antibiotic resistance.  
                                                        
5 See Antimicrobial Resistance, Fact Sheet, September 2016, World Health Org., 
http://www.who.int/mediacentre/factsheets/fs194/en/ (last visited Nov. 30, 2016).  
6 See Antibiotic/ Antimicrobial Resistance, Centers for Disease Control and Prevention,  
https://www.cdc.gov/ (“CDC Antimicrobial Resistance”) 
7 See Brian Krans, Few New Drugs: Why The Antibiotic Pipeline Is Running Dry, Healthline (July 22, 2014) 
http://www.health-line.com/health/antibiotics/why-pipeline-running-dry (“Healthline 2014”) (“The 
resistance rates we saw in the ‘90s were at 10 to 15 percent. Now it’s up to 60 percent in hospitals”) (last 
visited Nov. 30, 2016) 







The earliest believed use of antibiotics was in between 350 – 550 C.E, where tetracycline 
was used in Egypt.8  However, the modern era of antibiotics started in the first half of the 20th 
century, when Sir Alexander Fleming first discovered that blue-green mold prevented the growth 
of staphylococcus in a petri dish.9  A mycologist (mis)identified the mold as Penicillum rubrum, 
and subsequently Sir Alexander Fleming named the broth filtrate as penicillin.10  The term 
“antibiotic” was first coined by Selman Waksman to describe “any small molecule made by a 
microbe that antagonizes the growth of other microbes.”11  Penicillin was a very popular drug, 
primarily because of its ability to treat the infections quickly.12  Penicillin was heavily used by the 
Allied Troops during the World War-II.13  In addition to being useful in treatment of infections, 
antibiotics were also responsible for major advantages in medical science, primarily by reducing 
the risk of infection following surgical procedures.14  Moreover, soon after discovering that 
antibiotics were effective in treatment of diseases, food scientists also discovered that 
                                                        
8 See Bushak 2016, supra note 1. 
9 See Joan W Bennett and King-Thom Chung, Alexander Fleming and discovery of penicillin, 49 
ADVANCED IN APPLIED MICROBIOLOGY, 163, 168 (2001).  
10 Id. 
11 Clardy et al., The natural history of antibiotics, 19 CURRENT BIOLOGY, R437, R437 (2009). (“Clardy 
2009”)  
12 See Bushak 2016, supra note 1.  
13 Id.  
14 Budi Setiawan, The role of prophylactic antibiotics in preventing perioperative infection, 43 ACTA MED 
INDONES J INTERNAL MED, 262, 262 (2011) (“Antibiotic prophylaxis is one of important modalities 
in preventing surgical site infection. Antibiotic prophylaxis administration significantly reduces the 
incidence of surgical site infection up to four-fold of decrease.”)  






administration of antibiotics to livestock, especially chicken, increased their growth rate.15  This 
discovery led to the wide-scale use of antibiotics in agriculture.  
The problem with antibiotic resistance started soon after the discovery of antibiotics 
themselves.  Penicillin was widely used and it was successful in containing bacterial infections of 
World War II soldiers.16  However, soon scientists discovered that penicillin-resistant antibacterial 
infections had become a substantial clinical problem.17  Even Sir Alexander Fleming, in his Nobel 
Prize acceptance speech, recognized the problem of antibiotic resistance, and warned against the 
problem of development of resistant bacteria as a result of under-dosing penicillin.18  The primary 
reason for rapid development of antibiotic resistance is the ability of bacteria to “transfer genes 
horizontally — from one bacteria to another immediately — its ability to share resistance.”19  The 
rates of resistant staphylococcus infections in hospitals rose by 14% from 1946 to 1948.20 
After the discovery of penicillin-resistant bacteria, in an effort to defeat penicillin-resistant 
strains, scientists developed another antibiotic, methicillin.  Methicillin was initially successful in 
treatment of penicillin resistant infections, but within a year, strains resistant to methicillin were 
also discovered – methicillin resistant Staphylococcus aureus (“MRSA”).21  Yet another class of 
                                                        
15 Bushak 2016, supra note 1.  
16 See Ventola 2015, supra note 2, at p. 277.  
17 Id. 
18 Sir Alexander Fleming, Nobel Lecture (1945) available at http://www.nobelprize.org/-
nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf (last visited Nov. 30, 2016) (“Fleming Nobel 
Acceptance Speech”).  
19 Bushak 2016, supra note 1.  
20 Id. (“According to Harvard Magazine, resistant staph infections in hospitals had risen from 14 percent in 
1946 to 59 percent in 1948.”). 
21 Id. (“But within a year, bacterial strains developed resistance to methicillin too — eventually called 
MRSA , methicillin-resistant Staphylococcus aureus , or S. aureus . Now, MRSA can resist most antibiotics, 






antibiotics known as beta-lactams were developed as an agent effective against antibiotic resistant 
bacteria.22  These beta-lactams were deployed clinically with good results.23  However, beta-
lactam resistant infections were soon discovered both in the UK and USA.24  In 1972, vancomycin, 
a newly developed antibiotic, was introduced for treatment of the previously known antibiotic 
resistant infections.25  It was initially thought that it would be hard to develop resistance to 
vancomycin, but by 1979, there were reports of infections resistant to vancomycin.26  From 1950 
– 1970s, many new antibiotics were developed for treatment of infections including, endocarditis, 
plague, respiratory tract infections, and meningitis.27  The new antibiotics were made available to 
the public readily, which eventually paved the way for development of antibiotic resistance.  With 
time, some bacteria also became resistant to multiple antibiotics, these bacteria cause multi-drug 
resistant (MDR) infections. 
During the 1990s, MDR MRSA began to infect healthy people in the United States.  By 
2005, “over 100,000 Americans were stricken with MRSA infections and some 20,000 died, more 
than the amount of people who were dying from HIV and tuberculosis combined.”28  Previously, 
help in combating antibiotic-resistant infections was provided by discovery of new antibiotics.  For 
                                                        
and infections are common in hospitals — making it one of the biggest forerunners of multiple-drug 
resistant (MDR) bacteria.”). 
22 See Ventola 2015, supra note 2, at p. 277.  
23 See id. 
24 See id.  
25 See id.  
26 See id., p. 278.  
27 See Bushak 2016, supra note 1.  
28 Id. 






example, starting in the 1960’s the pharmaceutical industry introduced a variety of antibiotics, 
including, inter alia, streptomycin, chloramphenicol, and tetracycline, to combat the problem of 
antibiotic resistance.29  However, in the past few years, the pipeline of antibiotics has begun to 
dry.  From 2009 to 2014, the FDA has approved only two systemic antibiotics, which is a 88% 
drop from mid-1980s.30  The major reason for the reduction in number of new antibiotics 
developed by the pharmaceutical industry is the lack of return on investment on developing a drug 
which might lose efficacy shortly after getting approved.31  
III. Causes of Antibiotic Resistance: 
As discussed above, development of antibiotic resistance is the inevitable outcome of using 
antibiotics.  However, as discussed below, through careless use of antibiotics, humans have 
contributed in the acceleration of development of antibiotic resistance.  Although there might be 
additional reasons for development of antibiotic resistance, the primary causes recognized by the 
scientific community are discussed in this paper. 
1. Over-prescription of antibiotics: 
Over-prescription of antibiotics is one of the primary causes of development of antibiotic 
resistance.  As discussed above, the fundamental effect of administration of antibiotics is that it 
stops the growth of bacteria that are sensitive to the antibiotic, whereas it has no effect on the 
growth of bacteria that are insensitive or resistant to the antibiotic.32  Thus, administration of 
                                                        
29 See Clardy 2009, supra note 11, at p. R437; see also Ventola 2015, supra note 2 at p. 278.  
30 See Healthline 2014, supra note 7. 
31 Id. 
32 Get Smart: Know When The Antibiotics Work, Centers for Disease Control and Prevention, 
http://www.cdc.gov/getsmart/-community/about/antibiotic-resistance-faqs.html (“Every time a person 
takes antibiotics, sensitive bacteria (bacteria that antibiotics can still attack) are killed, but resistant bacteria 






antibiotics to treat any infection leads to a preferred selection for the growth of bacteria resistant 
to antibiotic over the sensitive bacteria.  As the use of antibiotics increases, it will inevitably lead 
to more instances of growth of resistant bacteria, resulting in development of antibiotic resistance.  
According to CDC, approximately half of antibiotics administered to humans are “unnecessary 
and inappropriate and make everyone less safe.”33 
In modern medicine, physicians rely heavily on antibiotics to treat infections.34  However, 
recent studies have demonstrated that “at least 30 percent of antibiotics prescribed in the United 
States are unnecessary.”35  Specifically, one study found that “most of these unnecessary 
antibiotics are prescribed for respiratory conditions caused by viruses – including common colds, 
viral sore throats, bronchitis, and sinus and ear infections – which do not respond to antibiotics.”36  
Moreover, this trend of needless prescription of antibiotics is also observed in countries other than 
the United States.  For example, in the United Kingdom, a majority of primary care antibiotic 
prescriptions are for the treatment of respiratory tract infections.37  The efficacy of antibiotics for 
                                                        
are left to grow and multiply. This is how repeated use of antibiotics can increase the number of drug-
resistant bacteria.”) (last visited Nov. 30, 2016) 
33 About Antimicrobial resistance, Centers for Disease Control and Prevention (September 8, 2015), 
https://www.cdc.gov/drugresistance/about.html (“[u]p to half of antibiotic use in humans and much of 
antibiotic use in animals is unnecessary and inappropriate and makes everyone less safe.”) (last visited Nov. 
30, 2016) 
34 See Carl Llor and Lars Bjerrum, Antimicrobial resistance: risk associated with antibiotic overuse and 
initiatives to reduce the problem, 5 THERAPEUTIC ADVANCES IN DRUG SAFETY, 229, 230 (2014) 
(“Llor 2014”) (“Most of the antibiotics used in medicine are prescribed by general practitioners (GP)”).  
35 CDC: 1 in 3 antibiotic prescriptions unnecessary, Centers for Disease Control and Prevention, Press 
Release (May 3, 2016) http://www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html 
(last visited Nov. 30, 2016) (“CDC May 3, 2016 Press Release”) 
36 Id., see also Llor 2014, supra, note 34 at p. 229 (“Antibiotic overprescribing is a particular problem in 
primary care, where viruses cause most infections.”).  
37 See Llor 2014, supra, note 34 at p. 230 (“In fact, primary care accounts for 80–90% of all antibiotic 
prescriptions in Europe and most antibiotics are prescribed for respiratory tract infections.”).  






treatment of respiratory tract infections, even if they are bacterial, is modest in the best case 
scenario.38  Research in Europe has demonstrated that the incidence of antibiotic resistance in a 
country depends on the amount of antibiotics consumed in that country.39  Thus, unnecessary 
prescription of antibiotics will lead to rise in the cases of antibiotic resistance.  
In addition to contributing to development of antibiotic resistance, unnecessary 
prescription of antibiotics can have other unintended health and economic consequences.  For 
example, it can lead to substantial over-expenditure in managing uncomplicated illnesses.40  
Moreover, over-prescription can also lead to “increased risk of adverse effects, more frequent re-
attendance and increased medicalization of self-limiting conditions.”41  In an effort to reduce the 
problem of, inter alia, over-prescription, CDC issued guidelines for treatment of upper respiratory 
tract infections.42  However, in spite of such guidelines, the incidences of over prescription of 




                                                        
38 Id. at p. 231 (“The benefits of antibiotic therapy for most respiratory tract infections are modest in the 
best-case scenario.”). 
39 Id. at p. 230 (“Countries with a higher consumption of antibiotics show higher rates of resistance.”). 
40 Xu et al., Over-prescribing of antibiotics and imaging in the management of uncomplicated URIs in 
emergency departments, 13 BMC EMERGING MEDICINE, 13, 13 (2013) (“Xu 2013”) (“Inappropriate 
testing and treatments can lead to substantial over-expenditure in managing uncomplicated illnesses.”).  
41 Llor 2014, supra note 34 at p. 229.  
42 See Troy Brown, CDC, ACP Issue Guideline on Antibiotic Use for RTIs, MedScape (January 18, 2016)  
http://www.medscape.com/viewarticle/857404  
43 Xu 2013, supra note 40 at p. 13 (“Despite the recommendations and campaign efforts by the CDC and 
many medical associations, the prescribing of antibiotics in treating uncomplicated URIs in the EDs remains 
prevalent.). 






2. Use of antibiotics in soaps, detergents, and other household cleaners: 
The use of antibiotics in household products, such as soaps, detergents and cleaners has 
increased substantially in the past few years.44  Some of the newer products where antibiotics are 
present now include window cleaners, chopsticks, plastic silverware, and mattresses.45  A study 
published in 2001 showed that antibacterial agents were present in at least 76% of liquid soaps and 
29% of bar soaps available in the United States.46  Numerous studies have demonstrated that that 
there is little to no benefit of the presence of antibiotics in these household products.47  Moreover, 
research shows that use of antibiotics like triclosan in soaps contributed to increase in antibiotic 
resistance in lab experiments.48  
After decades of research showing that antibiotics in household cleaners are potentially 
harmful, in 2013, FDA proposed a rule to “require manufacturers of antibacterial hand soaps and 
body washes to demonstrate that their products are safe for long-term daily use and more effective 
                                                        
44 Stuart B. Levy, Antibacterial Household Products: Cause for Concern, 7 EMERGING INFECTIOUS 
DISEASES, suppl. 3, 512, 512 (2001) (“Levy 2001”) (“Seven years ago, only a few dozen products 
containing antibacterial agents were being marketed for the home. Now more than 700 are available. The 
public is being bombarded with ads for cleansers, soaps, toothbrushes, dishwashing detergents, and hand 
lotions, all containing antibacterial agents.”).  
45 Id. (“Among the newer products in the antibacterial craze are antibacterial window cleaner and 
antibacterial chopsticks. Antibacterial agents are now in plastic food storage containers in England. In Italy, 
antibacterial products are touted in public laundries. In the Boston area, you can purchase a mattress 
completely impregnated with an antibacterial agent. Whole bathrooms and bedrooms can be outfitted with 
products containing triclosan (a common antibacterial agent), including pillows, sheets, towels, and 
slippers.”).  
46 See Perencevich et al., National and regional assessment of the antibacterial soap market: A step toward 
determining the impact of prevalent antibacterial soaps, 29 AMERICAN JOURNAL OF INFECTION 
CONTROL, 5, 281, 281 (2001) (“Perencevich 2001”).  
47 Aiello et al, Consumer Antibacterial Soaps: Effective or Just Risky?, 45 CLINICAL INFECTIOUS 
DISEASES,, S137, S137 (2007) (“Aiello 2007”) (“Soaps containing triclosan within the range of 
concentrations commonly used in the community setting (0.1%–0.45% wt/vol) were no more effective than 
plain soap at preventing infectious illness symptoms and reducing bacterial levels on the hands”).   
48 See id. at S137.  






than plain soap and water in preventing illness and the spread of certain infections.”49  Under this 
proposed rule, if companies are not able to demonstrate the efficacy of antibiotics present in the 
product, those products will need to be reformulated.50  On September 2, 2016 FDA issued a rule 
to ban marketing of over-the-counter (OTC) products containing certain antibiotics including, inter 
alia, triclosan and triclocarban.51  This new rule from FDA was specifically directed to products 
intended to be used with water.  However, this rule did not affect products such as “hand 
‘sanitizers’, wipes, or antibacterial products used in healthcare settings.”52  According to this rule, 
products such as toothpastes, shaving creams, cosmetics, hand sanitizers, and wipes containing 
antibiotics can still be marketed.  For example, a list of products containing triclosan, which is 
banned in soaps, includes, inter alia, deodorants and body spray.53  The presence of antibiotics in 
these household products without any proven benefit may accelerate the development of antibiotic 
resistance.  
 
                                                        
49 FDA issues proposed rule to determine safety and effectiveness of antibacterial soaps, FDA News 
Release (Dec. 16, 2003), 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm378542.htm (last visited Nov. 30, 
2016). 
50 See id. 
51 See FDA issues final rule to determine safety and effectiveness of antibacterial soaps, FDA News Release 
(Sept. 2, 2016), http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517478.htm 
(“FDA Press Release Sept. 2, 2016”) (“This final rule applies to consumer antiseptic wash products 
containing one or more of 19 specific active ingredients, including the most commonly used ingredients – 
triclosan and triclocarban.”) (last visited Nov. 30, 2016). 
52 Id. 
53 See Triclosan, Household Products Database, Health & Safety Information for Household Products, 
https://householdproducts.nlm.nih.gov/cgi-
bin/household/brands?tbl=chem&id=75&query=triclosan&searchas=TblChemicals (last visited Nov. 30, 
2016). 






3. Use of Antibiotics in Agriculture and Poultry 
In 1948, Robert Stokstad and Thomas Jukes discovered that poultry that had been fed broth 
with antibiotics in them grew 24% more than the poultry not receiving these antibiotics.54  “This 
discovery jumpstarted the process of routinely injecting antibiotics into animals.”55  Since then, 
“[a]ntibiotics are widely used in food-producing animals.”56  Most of the antibiotics used in 
livestock are not used as veterinary medicine, but rather in sub-therapeutic doses for increasing 
growth of farmed animals.57  Today, around 13 million kilograms of antibiotics are administered 
to livestock, which amounts to approximately 80% of all antibiotics used in the United States.58   
As discussed above, administration of sub-therapeutic doses of antibiotics leads to 
development of antibiotic-resistant bacteria.  Thus, it is not unsurprising that administration of 
subtherapeutic doses of antibiotics to livestock has been connected with development of antibiotic 
resistance.59  As the sub-therapeutic doses of antibiotics are administered to the animals, it kills 
the bacteria sensitive to the administered antibiotic, whereas the resistant bacteria continue to 
thrive.60  For example, in 2013, “a Consumer Reports investigation showed that over half of ground 
                                                        
54 See Bushak 2016, supra note 1. 
55 Id. 
56 NARMS - Combating Antibiotic Resistance with Surveillance, Centers for Disease Control and Prevention 
(Oct. 26, 2016), http://www.cdc.gov/narms/animals.html (last visited Nov. 30, 2016) (“CDC NARMS 
2016”). 
57 See Chang et al., Antibiotics in agriculture and the risk to human health: how worried should we be?, 8 
EVOLUTIONARY APPLICATIONS, 3, 240, 240 (2015) (“Chang 2015”).  
58 See id. at p. 240.  
59 Chang 2015, supra note 57 at p. 240; see also Mathew A.G. et al., Antibiotic Resistance in bacteria, 4 
FOODBORNE PATHOGEN DISEASES 2, 115, 115 (2007) (“However, use of antibiotics for agricultural 
purposes, particularly for growth enhancement, has come under much scrutiny, as it has been shown to 
contribute to the increased prevalence of antibiotic-resistant bacteria of human significance.”).  
60 See CDC NARMS 2016, supra note 56. 






turkey meat sold in the U.S. contained strains of drug-resistant bacteria.” 61  The resistant bacteria 
present in animals can be transferred to humans by simply ingesting the animals.62  Thus, a 
resistant bacteria strain may easily be transmitted to humans or other animals in contact with the 
infected livestock.  
In 1996, the government established the National Antimicrobial Resistance Monitoring 
System (NARMS) to increase collaboration amongst CDC, FDA, the U.S. Department of 
Agriculture (USDA), and state and local public health departments.63  An important objective for 
NARMS was to track antibiotic resistance in bacteria commonly transmitted through food.64  In 
2013, FDA announced that it was “implementing a voluntary plan with industry to phase out the 
use of certain antibiotics for enhanced food production.”65   One of the goals of FDA is to phase 
out the use of “medically important” drugs (used for treatment in humans) in the livestock feed.66  
The underlying rationale is that if the animals are not provided the “medically important” drugs, 
the bacteria in livestock are unlikely to develop resistance to such antibiotics.  In 2015, FDA issued 
further regulations directed to collecting the sales data for antibiotics to be used in livestock feed.67  
In a detailed study to evaluate the economic impact of use of antibiotics in livestock feed, the 
                                                        
61 Bushak 2016, supra note 1. 
62 See CDC NARMS 2016, supra note 56. 
63 See id. 
64 See id. 
65 Phasing Out Certain Antibiotic Use in Farm Animals, FDA Consumer Updates (Dec. 11, 2013), 
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm378100.htm (last visited Nov. 30, 2016). 
66 See id.  
67 See FDA Releases Biannual Progress Report, Announces Public Meeting on Use of Antimicrobials in 
Food-producing Animals, FDA CVM Updates (Aug. 21, 2015) (“FDA Progress Report Aug. 21, 2015”) 
http://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm459365.htm (“FDA Updates Aug. 
21, 2015”) (last visited Nov 28, 2016). 






authors concluded: “the efficacy of antibiotics in increasing farm-level productivity has decreased 
. . . European countries that have stopped using growth-promoting antimicrobials, U.S. producers 
are likely to adopt alternative practices in place of antibiotics for production purposes.”68 
4. Non-adherence to medical advice  
Non-adherence (also known as non-compliance) is defined as: “any deviation by a patient 
from a doctor’s instructions.”69  Non-adherence to prescribed doses could occur when the patients 
forget to take the prescribed dose of medication or prematurely discontinue the medication when 
they start feeling better while recovering from an infection or illness.70  Another form of misuse 
of antibiotics is self-medication using antibiotics.  Self-medication involves administering 
antibiotics without any direction from a physician.  In most of the cases, self-medication leads to: 
“unnecessary, inadequate, and ill-timed dosing.”71  The problem of self-medication with 
antibiotics is more prevalent in developing nations, where antibiotics are readily available without 
a prescription.72 
The problem of suboptimal dosing was predicted by Sir Alexander Fleming, who discussed 
the potential development of antibiotic resistance due to suboptimal dosing of antibiotics in his 
                                                        
68 Stacy Sneeringer, James MacDonald, Nigel Key, William McBride, Ken Mathews Economics of 
Antibiotic Use in U.S. Livestock Production Economic Research Report, United States Department of 
Agriculture (Nov. 2015), p. 59, available at,  http://www.ers.usda.gov/media/1950577/err200.pdf (last 
visited Nov. 30, 3016).  
69 Przemyslaw Kardas, Patient compliance with antibiotic treatment for respiratory tract infections, 49 
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 897, 897 (2002) (“Kardas 2002”).  
70 See Factors Contributing to the Emergence of Resistance, in The Resistance Phenomenon in Microbes 
and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop 
Summary. (Knobbler S.M. et al., ed. 2003) available at https://www.ncbi.nlm.nih.gov/books/NBK97126/ 
(last visited Nov. 30, 2016) 
71 Id.  
72 See id.  






Nobel acceptance speech.73  Non-adherence to prescribed doses is not advisable for patients.  Non-
adherence to prescribed doses is one of the main reasons for the failure of short-term antibiotic 
treatment leading to ineffective management of the disease.74  More importantly, “[n]on-adherence 
to antibiotic therapies may result in antibiotic resistance, as suboptimal doses of antibiotic therapy 
can result in insufficient antibiotic exposure for eradicating infectious bacteria and potentially 
create an environment that promotes antibiotic resistance.”75  If there is suboptimal dosing of 
antibiotic for treatment of an infection, bacteria that are developing resistance to antibiotics will 
continue to proliferate, leading to development of antibiotic resistance.  In an effort to combat the 
problem of non-adherence to prescribed dosing, CDC has encouraged pharmacies where antibiotic 
prescriptions are filled to post flyers demonstrating, the importance of completing the prescribed 
dose of antibiotics.76  
IV. Strategies for combating antibiotic resistance 
The development of antibiotic resistance is a natural effect of the administration of 
antibiotics.  Although antibiotics have been around for centuries, human (mis)use of antibiotics 
after discovery of penicillin, has been responsible in accelerating the development of antibiotic 
resistance.  In order to combat the problem of antibiotic resistance there are two primary 
                                                        
73 Fleming Nobel Acceptance Speech, supra, note 18 (“Then there is the danger that the ignorant man may 
easily under-dose himself and by exposing his microbes to non-lethal quantities of the drug make them 
resistant.” 
74 See Kardas 2002, supra note 69 at p. 897.  
75 Antibiotic Resistance, Pharmaceutical Group of the European Union, http://www.pgeu.eu-/en/policy/6-
antibiotic-resistance.html (last visited Nov. 30, 2016). 
76 See Get Smart: Know When Antibiotics Work, Centers for Disease Control and Prevention (Apr. 17, 
2015), https://www.cdc.gov/getsmart/community/programs-measurement/national-activities/antibiotics-
work.html (last visited Nov. 30, 2016). 






approaches: preventative measures and remedial measures.  The preventative measures are 
directed to decelerate the rate of development of antibiotic resistance, especially due to factors 
related to human involvement.  The remedial measures are focused on developing new lines of 
treatments for patients who are currently or in future might suffer from infections caused by 
antibiotic resistant bacteria.  These two approaches should be developed in conjunction with each 
other to combat the threat of antibiotic resistance.    
1. Preventative Solutions:  
The essence of developing preventative solutions is to curb the human use (or misuse) of 
antibiotics, which is the primary cause of development of antibiotic resistance.  According to Dr. 
Marc Sprenger, Director of the WHO’s secretariat for antimicrobial resistance, “. . . we are 
speeding up the process [of development of antibiotic resistance] dramatically by using antibiotics 
too much and often in the wrong contexts. We need to slow down the development and spread of 
resistance so that the antibiotics we have continue to work for as long as possible.”77   
In the past few years, some of the policies promulgated by the government, in conjunction 
with CDC and FDA, have tried to reduce the misuse of antibiotics by humans.  The approaches 
undertaken by the FDA include, inter alia,: (i) prohibiting the use of antibiotics in some household 
cleaning products without demonstrated efficacy; (ii) promoting patient adherence to the 
prescribed dosing regimen; and (iii) discouraging the use of antibiotics in livestock except in cases 
of medical necessity.78  For example, in order to reduce the use of antibiotics in household cleaning 
                                                        
77 Marc Sprenger, How to stop antibiotic resistance? Here's a WHO prescription, World Health 
Organization (Nov. 20, 2015), http://www.who.int/mediacentre/commentaries/stop-antibiotic-
resistance/en/ (last visited Nov. 30, 2016). 
78 See id. 






products, the FDA banned the use of antibiotics in soaps unless the companies demonstrate the 
utility of these antibiotics in the cleaning products.79  The government has also issued directives 
to prevent the use of antibiotics in livestock feed, except as required by medical necessity.80  
Although these efforts to slow down the development of antibiotic resistance are crucial, this paper 
primarily discusses approaches to reduce the misuse of antibiotics in medical settings, i.e., 
antibiotics prescribed by physicians.   
As discussed in detail above, over-prescription of antibiotics in medical settings is one of 
the primary reasons for development of antibiotic resistance.  Antibiotics are often unnecessarily 
prescribed by physicians for treatment of diseases that cannot be treated by antibiotics.  In addition 
to administration of antibiotics for diseases not treatable by antibiotics, due to lack of information 
about the infection(s), physicians often prescribe “powerful antibiotics that should ideally be kept 
in reserve, just in case their infection is caused by a drug-resistant strain that would not be cured 
by older medicines.”81  The fundamental problem is that the physicians often do not have sufficient 
information to prescribe the right drug to the right patient at the right time.82  
In many instances, physicians prescribe antibiotics for treatment of conditions that are not 
treatable by administration of antibiotics.  In an effort to reduce the over-prescription of antibiotics, 
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there are stewardship programs counseling physicians and patients for prudent use of antibiotics.83  
In 2010, the CDC launched a campaign known as “Get Smart for Healthcare,” focusing on 
improving the prescription of antibiotics in healthcare settings.84  In France, a similar campaign to 
educate physicians about the proper use of antibiotics in community settings led to a 25% decrease 
in the use of antibiotics.85  However, despite these efforts, the misuse of antibiotics in healthcare 
settings is prevalent, and it continues to be the leading cause of development of antibiotic 
resistance.86  
Even if a patient is suffering from a bacterial infection, the problem of misuse of antibiotics 
is exacerbated by physicians often being unable to determine the identity of the bacteria prior to 
prescribing antibiotics for that infection.  In most of the cases, the antibiotics are prescribed by 
physicians lacking specialized training in dealing with infectious diseases.87  The approach that 
physicians currently employ to prescribe antibiotics is based on their practical experience by 
assessment of patients’ symptoms.88  Such an approach for treatment using antibiotics is one of 
the major reasons for misuse of antibiotics, which leads to development of antibiotic resistance.  
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Recently, there has been a push to explore the application of rapid point-of-care diagnostic 
tests to determine the type of infection prior to administration of antibiotics.89  Rapid diagnostic 
tests (RDTs) are defined as “a type of point-of-care diagnostic, meaning that these assays are 
intended to provide diagnostic results conveniently and immediately to the patient while still at the 
health facility, screening site, or other health care provider.”90  In addition to providing results to 
the patients, RDTs will also provide critical information about the infection to the physicians 
treating the patient.  This information has demonstrated to be useful.  For example, the diagnostic 
tests performed on HIV-1 patients enabled physicians to diagnose HIV-1 strain resistance and 
prescribe effective antiviral drugs.91  A recent study conducted for critically ill patients in the ICU 
demonstrated that RDT provides rapid pathogen identification (6 hours).92  As noted by CDC, in 
excess of 10 rapid influenza diagnostic tests (RIDTs) have been approved by the FDA.93  
In spite of research demonstrating the usefulness of RDT methods for diagnosis of 
infections, and their undeniable medical and economic value, such tests have not been widely 
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adopted in the healthcare system.94   In general, the high cost of implementation of RDTs have 
been widely cited as the reason for absence of commonplace application of such tests.95  A second 
concern often raised is the cost-effectiveness of RDTs in patient-management, i.e., whether RDT 
in question has sufficient “clinical value” to be implemented.96  The factors analyzed in 
determining clinical value often involve, inter alia, whether the RDT will improve the 
understanding of the patient’s medical condition, whether there is a cheaper option available, and 
whether the condition is manageable without ordering the RDT.97  Healthcare providers also 
consider whether insurance companies will reimburse the cost of conducting RDTs.98  Finally, 
lack of investment in developing new RDTs is also limiting nationwide implementation of these 
tests in treatment of diseases.99  
Prescribing antibiotics without first conducting RDTs is generally less expensive.  Thus, 
for hospitals, doctors, and pharmacists, the diagnostic test is likely to be perceived as an 
unnecessary cost for healthcare facilities that may already be strained financially.100  However, 
this is a very narrow view on the issue of costs.  As discussed above, drug-resistant infections place 
a large drain on the healthcare system in the long run.  For example, a recent study showed that “a 
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resistant infection costs between 18,588 USD and 29,069 USD per patient.”101  First, even if RDTs 
are employed even at a fraction of this cost per patient, it would lead to significantly higher savings 
later during the course of treatment.  RDTs would likely reduce the misuse of antibiotics, which 
in turn would slow the development of antibiotic resistance, thus reducing the overall cost of 
healthcare.  Second, if RDTs are used routinely, it would significantly reduce the amount of 
antibiotics prescribed, reducing the cost of healthcare by not paying for the antibiotics.  Third, 
even the patients who are likely to shoulder the initial cost of implementation of RDTs either 
directly in their personal healthcare expenditure, or indirectly by higher cost of insurance, will 
benefit by a reduced likelihood of suffering from infections pursuant to antibiotic resistant bacteria.   
These advantages, even if they do not completely offset the immediate cost of implementation of 
RDTs, should provide a compelling reason for implementation of RDTs.    
In the past few years, the technology for detection and analysis of bacteria infecting the 
patients has advanced significantly.102  The newly developed techniques are increasing the 
specificity, sensitivity, and the speed of detection of microbial infections, as well as reducing the 
costs of implementing such tests.  Specifically, the advent of techniques such as polymeric chain 
reaction (PCR) and nucleic acid-based technologies (NAATs) that enable genetic sequencing of 
pathogens has been immensely helpful in diagnosis of infections as well as development of new 
drugs.103  These technologies have enhanced the diagnosis of bacterial and viral infections.  In the 
more recent advances for RDTs, the development of nanotechnology based tests that do not require 
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addition of various reagents, has resulted in the use of such tests in the point of care for clinical 
treatment.104  Indeed, in 2011 and 2012, FDA approved numerous molecular diagnostic tests for 
detection of strains of bacteria.105 
The development and implementation of new RDTs will be an invaluable tool in combating 
the misuse of antibiotics.  In an ideal setting, the RDT will primarily answer the following 
questions: (i) Is the infection bacterial or viral; and (ii) If the infection is bacterial, what kind of 
bacteria is causing the infection.106  This information will be crucial for physicians to design an 
efficient treatment for the patients.  In an Executive Order issued on September 18, 2014, President 
Obama announced a strategy to combat antibiotic resistance by, inter alia, “develop[ing] and 
[promoting] the use of new, rapid diagnostic technologies.”107  A prize of up to $20 million was 
also announced for: “the first group(s) to develop a rapid, point-of-care diagnostic test to be used 
by health care providers to identify highly resistant bacterial infections.”108  Although these 
initiatives would be undoubtedly helpful to spur innovation in developing new RDT to be used in 
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clinical management of diseases, recent analysis has noted that in order to be more effective, the 
prize amounts for spurring innovations needs to be higher.109  
In addition to these reward-based innovation approaches, other ideas have also been 
suggested to accelerate the innovation for development of new RDTs.  For example, to ease the 
concern of high implementation cost, it might be helpful to create a global fund, which will 
subsidize the cost of implementation of new RDTs for healthcare providers.110  Another 
recommended use for the resources of this global fund is to invest in early stage research for new 
RDTs111.  This approach is particularly helpful in developing ground-breaking technology, where 
there is a high risk of failure that the private sector may not be willing to undertake.  There have 
also been recommendations for healthcare providers to play a critical role in development of RDTs 
by assisting in clinical trials and conducting cost-effectiveness studies.112  A combination of 
approaches such as these would indeed be beneficial for the development of new generation of 
RDTs.  
Finally, in addition to development of approaches to curb the needless use of antibiotics, 
further policy interventions are needed to make sure that the tests already developed are utilized 
in healthcare, especially prior to prescribing antibiotics.  Antibiotics stewardship programs are a 
step in the right direction, and they should take a stronger role in educating, advocating, and 
implementing RDTs in the modern healthcare paradigm.  As discussed above, with the rapidly 
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developing technology, a plethora of new RDTs are now available for the physicians to utilize in 
treatment of patients.  FDA, in conjunction with healthcare providers and insurance companies, 
should promulgate rules and policies which promote the implementation of RDTs that have 
demonstrated a high sensitivity and specificity in identifying the infections.  Government support 
in funding the initial implementation of the more expensive technologies will be immensely 
helpful for the increasingly cash-strapped healthcare system.  The cost of this initial investment is 
likely to be offset by the reduced amount time spent by patients receiving treatment for their 
infections. 
RDTs provide one of the most promising avenues to curb the unnecessary use of 
antibiotics, especially in the healthcare settings.  Policies directed towards development of new 
cost-effective RDTs with high sensitivity and specificity, and successfully implementing them in 
the modern healthcare paradigm will be crucial in halting the proliferation of antibiotic resistance 
due to over-prescription.  In combination with other policies designed to eradicate the misuse of 
antibiotics in other areas, such as in household cleaning products and animal feed, would go a long 
way in at least slowing the development of antibiotic resistance. 
2. Remedial Measures: 
Remedial measures to combat antibiotic resistance are directed to discovering new tools 
for treatment of the patients suffering from infections that are resistant to the available antibiotics.  
This is extremely important in combating antibiotic resistance.  There are some multi-drug 
resistant infections that are slowly becoming resistant to all available antibiotics.  For example, 






recently the WHO warned that “[w]e are running out of ways to treat gonorrhea.”113  WHO has 
released guidelines which recommends physicians to not prescribe an entire class of antibiotics 
(quinolones) for treatment of gonorrhea due to emergence of resistant strains of gonorrhea.114 
In general, the best remedial approach to combat antibiotic resistance is to continue to 
develop novel antibiotics.  However, after the initial boom in the development of antibiotics, the 
pipeline of antibiotics in the pharmaceutical industry is running dry.115   For example, there was a 
gap of 38 years between the launch of new (structural) classes of antibiotics.116  The primary reason 
for lack of interest from pharmaceutical industry for the development of antibiotics is the low ratio 
of revenues to cost of development.117  Antibiotics are generally short-term therapies designed to 
completely cure the disease.  Thus, once the disease is cured, the patient stops the consumption of 
antibiotics.118  Moreover, due to development of antibiotic resistance, the newly developed 
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antibiotics lose effectiveness over time.119  Pharmaceutical companies, often driven by high 
profits, prefer to develop medicines that do not lose effectiveness, such as drugs for diabetes or 
depression.120 
From the early days of development of antibiotics, the primary source of new antibiotics 
has been the pharmaceutical industry.  Thus, the government, in their efforts to develop new 
antibiotics, designed approaches to motivate the pharmaceutical industry to engage in research and 
development of new antibiotics.  In an effort to boost the development of new antibiotics, the 
government developed a “National Action Plan For Combating Antibiotic-Resistant Bacteria,” 
(“NAPCAB”) which proposed a higher degree of collaboration between the NIH and the 
pharmaceutical industry for development of infrastructure for clinical trials for molecules showing 
promising antimicrobial activity.121  NAPCAB also recommended the creation of a 
“biopharmaceutical incubator,” that brings together researchers, inventors, and start-up companies 
to develop new antibiotics and non-traditional therapies.122  In addition, Congress passed 
“Generating Antibiotic Incentives Now (GAIN)” Act, which was signed into law by President 
Obama in 2012.  GAIN includes a provision for additional five years of exclusivity for the new 
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“qualified” antibiotics approved by the FDA.123  The additional exclusivity is in addition to any 
other applicable exclusivity provision for that particular drug.124  GAIN also includes a provision 
for expedited approval of the antibiotics by the FDA.  By October 2013, at least 16 antibiotics had 
been designated as qualified.  In 2015, FDA approved two drugs, Avycaz® and Cresemba® under 
GAIN act.  Thus, the approach undertaken by the government to boost the development of 
antibiotics is generating some positive results.   
The government is trying to provide incentives that may reignite the interest of 
pharmaceutical companies to develop new antibiotics.  However, one of these approaches by the 
government, i.e., granting additional exclusivity to the newly approved antibiotics, is likely to have 
an unintended effect of contributing to antibiotic resistance.  For example, under a provision of 
GAIN, the newly developed “qualified” antibiotics might be entitled to additional exclusivity.  
When a pharmaceutical company is granted exclusivity to market a certain drug for a limited time, 
it is motivated to maximize the sales of the drugs during that period of exclusivity.  This leads to 
aggressive marketing of the “new” antibiotic to the medical service providers.  It is precisely this 
overuse of these new antibiotics, supposed to be our last-line of defense against infections caused 
by bacteria resistant to other available antibiotics that leads to development of resistance to these 
new antibiotics.  Thus, such policies, based on granting exclusivity to pharmaceutical companies 
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developing a new antibiotic is likely to have the unintended effect of promoting antibiotic 
resistance.  
Thus, a policy motivating the development of new antibiotics without the unintended 
consequence of promoting antibiotic resistance will overcome the flaw of current policies.  To this 
effect, a policy that gives the pharmaceutical company exclusivity until a certain quantity of drugs 
is sold, or until a set amount of revenue is generated from the sales of the antibiotic, will still 
motivate pharmaceutical companies to develop new drugs, but will not push them to aggressively 
market the new antibiotic.  A similar policy has been suggested previously by IDSA, which 
recommended “federally funded advanced purchase commitments or other ‘promised markets’ for 
priority antibiotics.”125  A strategy which ensures an innovator pharmaceutical company, which 
presumably has invested a great deal time and money in developing the new antibiotic, will be 
able to recoup the investment, does not incentivize the pharmaceutical companies to invest in 
marketing newly developed antibiotics.  Thus, such policies will encourage development of new 
antibiotics without the unintended consequence of fostering antibiotic resistance.  
Another similar proposed strategy is known as “transferable patent extensions,” “wild card 
patent term extensions,” or “wild card extensions.”126  Under this strategy, after receiving FDA 
approval for a new antibiotic, a pharmaceutical company would receive 6 months to 2 years of 
additional exclusivity on any other drug that the pharmaceutical company is marketing.127  
Although such a strategy may be considered risky, since it will most likely increase the cost of 
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other essential drugs, the pharmaceutical industry considers it the most likely to spur research for 
the development of new antibiotics.  Furthermore, “an academic analysis of the transferable patent 
extension concept has indicated that it likely will result in a net savings of billions of dollars in 
health care costs by promoting the availability of antibiotics to fight costly multidrug-resistant 
infections.”128 
Policies giving pharmaceutical companies enhanced exclusivity or intellectual property 
protection for a drug of their choice, that they are already marketing, is likely to spur their interest 
in developing new antibiotics for the treatment of antibiotic-resistant infections.  Moreover, 
carefully designed incentives, such as revenue-based or sales-based exclusivity will ensure that the 
above-mentioned intellectual property based protections do not lead to inadvertent development 
of bacteria resistant to the newly developed antibiotic. 
Finally, there has been some legislation introduced granting “tax credits” to the 
pharmaceutical industries engaging in the research and development of, inter alia, new antibiotics 
or diagnostic tools to fight infectious diseases.129  In addition to the proposed “tax credits,” 
Congress may also enact legislation that provides deductions for certain qualified research and 
development expenses directed to development of new antimicrobial drugs.  Such deductions 
would at least motivate pharmaceutical companies to engage in antimicrobial research to lower 
their tax liability.  Moreover, potentially, infrastructure development activities that qualify as tax 
deductible expenses for development of antibiotics, may also be used for development of other 
unrelated drugs.  Such an approach, might be particularly appealing to the pharmaceutical 
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company constantly looking for ways to lower their tax liability and maximizing their earnings, to 
engage in research and development associated with development of new antibiotics for fighting 
antibiotic resistant infections.    
V. Conclusion 
Antibiotic resistance was highlighted by Sir Alexander Fleming as a potential problem 
soon after his pivotal discovery of penicillin.  Development of antibiotic resistance has now 
become a modern day healthcare epidemic costing thousands of lives.  If we fail to take steps to 
solve this unprecedented challenge, the ability of healthcare providers to fight bacterial infections 
will be severely compromised.  In an effort to stem the problem of antibiotic resistance, 
coordinated policies directed at stemming the misuse of antibiotics, especially those prescribed by 
physicians, need to be advanced.  Although there are numerous approaches to tackle this problem, 
advancing the use of RDTs is likely to reduce the number of antibiotics prescribed by physicians 
significantly.  Thus, policies directed to incentivize the utilization of RDTs prior to prescription of 
antibiotics will be instrumental in curbing the development of antibiotic resistance.   
However, development of resistance amongst bacteria is inevitable upon use of antibiotics.  
Accordingly, in order to develop new antibiotics, to which the bacteria are sensitive, is important.  
Policies directed to spur innovation in research and development of new antibiotics by 
pharmaceutical industries that do not pressurize the innovating company to market the antibiotic 
aggressively are critical.  For example, policies supporting exclusivity till a fixed amount of sales 
for the newly developed antibiotics are most likely to spur innovation and prevent aggressive 
marketing of the antibiotics by the pharmaceutical companies.  In order to preserve the advances 
made in the past few decades for the ability of physicians to fight antibacterial infections, policies 






directed towards preventive and remedial measures to combat antibiotic resistance should be 
developed and vigorously advanced.    
